In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:

Challenges with the pathologic testing for HER2-low expression
Optimal treatment of patients with HER2-low advanced breast cancer
Role of TROP-2–targeted therapies
Management of ADC-associated adverse events to optimize treatment outcomes
ADCs on the horizon for patients with advanced breast cancer

Presenters:

Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Melinda Telli, MD
Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Link to full program:
https://bit.ly/49WxRBM

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer